Table 2.

Primary end point assessed 4 months after randomization

Primary end point	CT	BEV
	N = 45	N = 46
Tumor controlled	33 (73.3%)	36 (78.3%)
No QoL degradation >2	29 (64.4%)	27 (58.7%)
Efficacy co-criterion reached	26 (57.8%)	23 (50.0%)
No unexpected hospitalization	32 (71.1%)	30 (65.2%)
No grade 3–4 cardiovascular toxicity	41 (91.1%)	40 (87.0%)
Safety co-criterion reached	32 (71.1%)	28 (60.9%)
Both efficacy and safety end point reached	21 (46.7%)	16 (34.8%)